%0 Journal Article %A Rahul Ukey %A Natalie Bruiners %A Hridesh Mishra %A Pankaj K. Mishra %A Deborah McCloskey %A Alberta Onyuka %A Fei Chen %A Abraham Pinter %A Daniela Weiskopf %A Alessandro Sette %A Jason Roy %A Sunanda Gaur %A Maria Laura Gennaro %T Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2 %D 2021 %R 10.1101/2021.09.17.21263528 %J medRxiv %P 2021.09.17.21263528 %X Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class five months earlier on average. After controlling for time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Thus, a dichotomy exists between humoral and cellular responses elicited by the two vaccine classes. Our results have implications for the need of booster doses in vaccinated subjects and might explain the dichotomy reported between the waning protection from symptomatic infection by SARS-CoV-2 vaccination and its persisting efficacy in preventing hospitalization and death.Competing Interest StatementCompeting interests: Rutgers University has filed for patent protection for various aspects of anti-SARS-CoV-2 antibody detection and its uses. La Jolla Institute has filed for patent protection for various aspects of T cell epitope and vaccine design work. A.S. is a consultant for Gritstone, Flow Pharma, Arcturus, Immunoscape, CellCarta, Oxford Immunotec, and Avalia.Funding StatementThis work was funded by NIH grants R01 HL149450, R01 HL149450-S1, U01 AI122285-S1, and UL1 TR003017, and NIH contract 75N9301900065.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study activities were approved by the Rutgers Institutional Review Board (Pro2020000655).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author. %U https://www.medrxiv.org/content/medrxiv/early/2021/09/21/2021.09.17.21263528.full.pdf